Key result
Implementation of dapagliflozin in eligible patients with HFmrEF and HFpEF was projected to yield an absolute risk reduction of 1.3% for mortality and 5.1% for heart failure readmission at 1 year.
Why the study?
The study was designed to address the projected clinical benefits of dapagliflozin among patients with HFmrEF and HFpEF.
Does projected implementation of dapagliflozin reduce mortality and heart failure readmission in patients ≥50 years admitted with HFmrEF and HFpEF?
Cohort (n=4,049)
Yes
Does projected implementation of dapagliflozin reduce mortality and heart failure readmission in patients ≥50 years admitted with HFmrEF and HFpEF?
Projected implementation of dapagliflozin in a real-world Spanish cohort of HFmrEF/HFpEF patients suggests a substantial absolute risk reduction in 1-year mortality (1.3%) and heart failure readmissions (5.1%).
Answers are grounded in this paper and cite their sources.
Broad eligibility in HFmrEF/HFpEF cohorts; extends DELIVER applicability to internal medicine patients while leaving outcome benefits open.
Aims: To address the projected clinical benefits of dapagliflozin among patients with heart failure (HF) with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF). Methods: A multicenter, prospective, cohort study of patients ≥50 years admitted with HF to Spanish internal medicine departments. The projected clinical benefits of dapagliflozin were calculated from the DELIVER trial. Results: A total of 4049 patients were included; 3271 (80.8%) were eligible for dapagliflozin treatment, according to DELIVER criteria. Within 1 year after discharge, 22.2% were rehospitalized for HF and 21.6% died. Implementation of dapagliflozin would translate into an absolute risk reduction of 1.3% for mortality and 5.1% for HF readmission. Conclusion: HF patients with preserved or mildly reduced ejection fraction have a high risk of events. The use of dapagliflozin could substantially reduce the HF burden.
No takes yet. Share an insight, caveat, or question.
Montero-Pérez-Barquero et al. (2023) conducted a cohort in Heart failure with mildly reduced or preserved ejection fraction (n=4,049). Dapagliflozin was evaluated on Mortality and heart failure readmission (ARR 1.3% for mortality and 5.1% for HF readmission). Implementation of dapagliflozin in eligible patients with HFmrEF and HFpEF was projected to yield an absolute risk reduction of 1.3% for mortality and 5.1% for heart failure readmission at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: